OBJECTIVE To report the incidence of pancreatitis in type 2 diabetes trials of liraglutide and details of all pancreatitis cases.

RESEARCH DESIGN AND METHODS Data from Novo Nordisk–sponsored trials with liraglutide (phase 2 and 3; NN2211 identifiers) completed by 19 April 2013 were pooled. All pancreatitis cases were reviewed.

CONCLUSIONS Based on the small number of cases observed, the incidences of reported AP and CP were numerically greater with liraglutide than with comparators. Not all cases fulfilled diagnostic criteria, and confounding variables were present in 75% of the AP cases with liraglutide therapy, precluding firm conclusions.


Continue Reading

READ FULL ARTICLE Curated publisher From Diabetesjournals